A biotech company’s R&D showcase at a China industry summit, previewing updates on antibody–drug conjugates and T‑cell engager platforms.
Key Takeaways
- Commercial-stage global biotech company dedicated to discovering
- At the event, the Company presented updated clinical data for ATG–022 (CLDN18.2 antibody–drug conjugate )
- In addition, the Company also introduced ATG–207, a first–in–class αCD3-TGF-β bifunctional fusion protein